Catalyst Wire Dossier Catalyst Wire Dossier

MEDI-570

ICOS-targeting monoclonal antibody · AstraZeneca
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MEDI-570, covering 2014-08-26 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma [Phase 1]

See pricing